May 11 2021
Waters Corporation (NYSE:WAT) has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs.
“The BioAccord System moves attribute-based monitoring out of centralised MS labs and into the hands of more scientists in regulated and quality control laboratories who may not have extensive experience operating mass spectrometers,” said Jeff Mazzeo, Ph.D., Vice President – Global Marketing and Scientific Operations, Waters Corporation. “With this new method for the BioAccord System on the waters connect platform, scientists have a single, sensitive multiplexed method to accurately assess the most important attributes of protein-based drugs that enable rapid decision-making for product
Waters peptide multi-attribute method for BioAccord System boosts innovator and biosimilar drug development and commercialization
selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
Waters introduces new peptide multi-attribute method workflow
biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.